Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2025-09-23 Major Shareholding Noti…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is titled 'Major Shareholder Announcement' and explicitly states that Orbis Investment Management Limited has informed the company of a change in their shareholding (crossing the 5% threshold). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ). Although the document mentions attachments, the text itself provides the core details of the notification, making it a primary filing rather than just a report publication announcement.
2025-09-23 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a standard template for the 'Notification of Major Holdings', which is used by shareholders to report crossing ownership thresholds in a company. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-09-23 English
6-K
Foreign Filer Report
2025-09-10 English
6-K
Foreign Filer Report
2025-09-09 English
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document is titled 'Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons'. It explicitly references Article 19 of Regulation No. 596/2014 (Market Abuse Regulation), which is the standard regulatory requirement for reporting insider/director dealings. Although the document contains an attachment link, the text itself serves as the official notification of these transactions. Therefore, it is classified as a Director's Dealing (DIRS).
2025-09-09 English
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document is a formal notification of share transactions made by a person discharging managerial responsibilities (the CEO, Jan G. J. van de Winkel) at Genmab A/S. It explicitly references Article 19 of Regulation No. 596/2014 on Market Abuse, which is the standard regulatory framework for reporting insider/director dealings. The content provides specific details of the transaction, including the name of the person, the nature of the transaction (subscription of shares), price, volume, and date. This fits the definition of a 'Director's Dealing' (DIRS) filing.
2025-09-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.